Hanna N, Einhorn LH. Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol. 2014;32(28):3085–92.
Article
CAS
PubMed
Google Scholar
Calabrò F, Albers P, Bokemeyer C, Martin C, Einhorn LH, Horwich A, et al. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. Eur Urol. 2012;61:1212–21.
Article
PubMed
Google Scholar
Abouassaly R, Fossa SD, Giwercman A, Kollmannsberger C, Motzer RJ, Schmoll HJ, et al. Sequelae of treatment in long-term survivors of testis cancer. Eur Urol. 2011;60(3):516–26.
Article
PubMed
Google Scholar
Piketty AC, Flechon A, Laplanche A, Nouyrigat E, Droz JP, Theodore C, et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer. 2005;93:909–14.
Article
CAS
PubMed
PubMed Central
Google Scholar
Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18:2169–78.
CAS
PubMed
Google Scholar
Nuver J, Smit AJ, van der Meer J, van den Berg MP, van der Graaf WT, Meinardi MT, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005;23:9130–7.
Article
CAS
PubMed
Google Scholar
Dieckmann KP, Gerl A, Witt J, Hartmann JT, German Testicular Cancer Study Group. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol. 2010;21:1607–11.
Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120:617–24.
Article
CAS
PubMed
Google Scholar
O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14:91–6.
Article
PubMed
Google Scholar
Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw. 2006;4:1059–70.
CAS
PubMed
Google Scholar
O'Reilly A, Maceneaney P, Mayer N, O'Reilly SP, Power DG. Testicular cancer and platinum: a double-edged sword. J Clin Oncol. 2014;32(12):e46–8.
Article
PubMed
Google Scholar
International Germ Cell Cancer Consensus Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15(2):594–603.
Google Scholar
Brouha ME, Bloemendal HJ, Kappelle LJ, Winter JB. Cerebral infarction and myocardial infarction due to cisplatin-containing chemotherapy].[Article in Dutch. Ned Tijdschr Geneeskd. 2003;147:457–60.
CAS
PubMed
Google Scholar
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22.
Article
CAS
PubMed
Google Scholar
Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol. 2004;24(2):216–29.
Article
CAS
PubMed
Google Scholar
Page C, Rubin LE, Gusberg RJ, Dardik A. Arterial thrombosis associated with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and peripheral arterial disease: importance of synergistic factors. J Vasc Surg. 2005;42(5):1014–48.
Article
PubMed
Google Scholar
de Paula Sabino A, Ribeiro DD, Carvalho M, Cardoso J, Dusse LM, Fernandes AP. Factor V Leiden and increased risk for arterial thrombotic disease in young Brazilian patients. Blood Coagul Fibrinolysis. 2006;17(4):271–5.
Article
PubMed
Google Scholar
Mandegar MH, Saidi B, Roshanali F. Extensive arterial thrombosis in a patient with factor V Leiden mutation. Interact Cardiovasc Thorac Surg. 2010;11(1):127–9.
Article
PubMed
Google Scholar
Lopez F, Mega A, Schiffman F, Sweeney J. Splenic infarction from factor V Leiden mutation. Am J Hematol. 1999;62(1):62–3.
Article
CAS
PubMed
Google Scholar
De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004;50:187–96.
Article
PubMed
Google Scholar
Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011;2011:394740.
PubMed
PubMed Central
Google Scholar
Honecker F, Koychev D, Luhmann AD, Langer F, Dieckmann KP, Bokemeyer C, et al. Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy. Onkologie. 2013;36(11):663–8.
Article
CAS
PubMed
Google Scholar
Mandalà M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol. 2004;15(4):590–3.
Article
PubMed
Google Scholar
Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica. 2004;89(2):201–6.
PubMed
Google Scholar
Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK national cancer research institute upper gastrointestinal clinical studies group. J Clin Oncol. 2009;27(23):3786–93.
Article
CAS
PubMed
Google Scholar
Dieckmann KP, Struss WJ, Budde U. Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Res. 2011;31(12):4501–5.
CAS
PubMed
Google Scholar
Nuver J, De Haas EC, Van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep. 2010;23(1):247–53.
CAS
PubMed
Google Scholar
Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JO, Ehrenstein V, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case–control study. JAMA Intern Med. 2013;173(9):743–52.
Article
CAS
PubMed
Google Scholar
Xu Z, Westrick RJ, Shen YC, Eitzman DT. Pulmonary fibrosis is increased in mice carrying the factor V Leiden mutation following bleomycin injury. Thromb Haemost. 2001;85(3):441–4.
CAS
PubMed
Google Scholar